File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Comparison of components and anti-liver cancer activity in vitro between Huanglian and Yunlian
  • Basic View
  • Metadata View
  • XML View
TitleComparison of components and anti-liver cancer activity in vitro between Huanglian and Yunlian
 
AuthorsTo, C1
Liew, C1 2
Wang, X1 3
Wang, N1
Feng, Y1
 
Issue Date2012
 
PublisherOmics Publishing Group. The Journal's web site is located at http://www.omicsonline.org/jbbhome.php
 
CitationJournal Of Bioequivalence And Bioavailability, 2012, v. 4 n. 6, p. 86-90 [How to Cite?]
DOI: http://dx.doi.org/10.4172/jbb.1000118
 
AbstractObjective: Coptidis Rhizoma is a famous Chinese medicinal herb for its potential to combat cancer, inflammation, fibrosis, viral and bacterial infections, and oxidation. Coptis chinensis Franch (Huanglian in Chinese HL) and Coptis teeta Wall (Yun Huanglian or Yunlian YHL) are two species of Coptidis Rhizoma commonly used in Traditional Chinese Medicine. Huanglian is produced from Sichuan Province, while Yunlian comes from the Yunnan Province. Both provinces are located in China. There are indications that both herbs possess similar characteristics and functions in clinical use. However, there are no signs of prior research to compare the effects of HL and YHL on hepatocellular carcinoma. In this study, we compared the components and anti-liver cancer effects in vitro between Huanglian and Yunlian. Methods: HPLC was introduced to analyze the active components in Huanglian and Yunlian aqueous extracts. Liquid chromatography with mass spectrometry and High performance liquid chromatography with UV detector were used to identify and compare the main ingredients ratio between Huanglian and Yunlian extracts. Cytotoxicity and apoptosis affected by the two extracts on MHCC97L cell line was observed by using MTT assay and flow cytometry, respectively. The inhibition of metastasis and invasion in hepatocellular carcinoma cell line MHCC97L by Huanglian and Yunlian were compared as well. Results: Results of phytochemical analysis showed there were no significant differences between the two herbs' ingredients and ratios. Also, there were no significant differences between Huanglian and Yunlian on cytotoxicity, apoptosis and metastasis in MHCC97L. Conclusion: Yunlian and Huanglian share great similarities in both chemical compostion and bioactivity in vitro. © 2012 To C, et al.
 
ISSN0975-0851
2013 SCImago Journal Rankings: 0.176
 
DOIhttp://dx.doi.org/10.4172/jbb.1000118
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTo, C
 
dc.contributor.authorLiew, C
 
dc.contributor.authorWang, X
 
dc.contributor.authorWang, N
 
dc.contributor.authorFeng, Y
 
dc.date.accessioned2012-09-20T08:27:56Z
 
dc.date.available2012-09-20T08:27:56Z
 
dc.date.issued2012
 
dc.description.abstractObjective: Coptidis Rhizoma is a famous Chinese medicinal herb for its potential to combat cancer, inflammation, fibrosis, viral and bacterial infections, and oxidation. Coptis chinensis Franch (Huanglian in Chinese HL) and Coptis teeta Wall (Yun Huanglian or Yunlian YHL) are two species of Coptidis Rhizoma commonly used in Traditional Chinese Medicine. Huanglian is produced from Sichuan Province, while Yunlian comes from the Yunnan Province. Both provinces are located in China. There are indications that both herbs possess similar characteristics and functions in clinical use. However, there are no signs of prior research to compare the effects of HL and YHL on hepatocellular carcinoma. In this study, we compared the components and anti-liver cancer effects in vitro between Huanglian and Yunlian. Methods: HPLC was introduced to analyze the active components in Huanglian and Yunlian aqueous extracts. Liquid chromatography with mass spectrometry and High performance liquid chromatography with UV detector were used to identify and compare the main ingredients ratio between Huanglian and Yunlian extracts. Cytotoxicity and apoptosis affected by the two extracts on MHCC97L cell line was observed by using MTT assay and flow cytometry, respectively. The inhibition of metastasis and invasion in hepatocellular carcinoma cell line MHCC97L by Huanglian and Yunlian were compared as well. Results: Results of phytochemical analysis showed there were no significant differences between the two herbs' ingredients and ratios. Also, there were no significant differences between Huanglian and Yunlian on cytotoxicity, apoptosis and metastasis in MHCC97L. Conclusion: Yunlian and Huanglian share great similarities in both chemical compostion and bioactivity in vitro. © 2012 To C, et al.
 
dc.description.naturepublished_or_final_version
 
dc.identifier.citationJournal Of Bioequivalence And Bioavailability, 2012, v. 4 n. 6, p. 86-90 [How to Cite?]
DOI: http://dx.doi.org/10.4172/jbb.1000118
 
dc.identifier.doihttp://dx.doi.org/10.4172/jbb.1000118
 
dc.identifier.epage90
 
dc.identifier.hkuros208630
 
dc.identifier.hkuros217176
 
dc.identifier.issn0975-0851
2013 SCImago Journal Rankings: 0.176
 
dc.identifier.issue6
 
dc.identifier.scopuseid_2-s2.0-84866333908
 
dc.identifier.spage86
 
dc.identifier.urihttp://hdl.handle.net/10722/166083
 
dc.identifier.volume4
 
dc.languageeng
 
dc.languageUnited States
 
dc.publisherOmics Publishing Group. The Journal's web site is located at http://www.omicsonline.org/jbbhome.php
 
dc.relation.ispartofJournal of Bioequivalence and Bioavailability
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.titleComparison of components and anti-liver cancer activity in vitro between Huanglian and Yunlian
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>To, C</contributor.author>
<contributor.author>Liew, C</contributor.author>
<contributor.author>Wang, X</contributor.author>
<contributor.author>Wang, N</contributor.author>
<contributor.author>Feng, Y</contributor.author>
<date.accessioned>2012-09-20T08:27:56Z</date.accessioned>
<date.available>2012-09-20T08:27:56Z</date.available>
<date.issued>2012</date.issued>
<identifier.citation>Journal Of Bioequivalence And Bioavailability, 2012, v. 4 n. 6, p. 86-90</identifier.citation>
<identifier.issn>0975-0851</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/166083</identifier.uri>
<description.abstract>Objective: Coptidis Rhizoma is a famous Chinese medicinal herb for its potential to combat cancer, inflammation, fibrosis, viral and bacterial infections, and oxidation. Coptis chinensis Franch (Huanglian in Chinese HL) and Coptis teeta Wall (Yun Huanglian or Yunlian YHL) are two species of Coptidis Rhizoma commonly used in Traditional Chinese Medicine. Huanglian is produced from Sichuan Province, while Yunlian comes from the Yunnan Province. Both provinces are located in China. There are indications that both herbs possess similar characteristics and functions in clinical use. However, there are no signs of prior research to compare the effects of HL and YHL on hepatocellular carcinoma. In this study, we compared the components and anti-liver cancer effects in vitro between Huanglian and Yunlian. Methods: HPLC was introduced to analyze the active components in Huanglian and Yunlian aqueous extracts. Liquid chromatography with mass spectrometry and High performance liquid chromatography with UV detector were used to identify and compare the main ingredients ratio between Huanglian and Yunlian extracts. Cytotoxicity and apoptosis affected by the two extracts on MHCC97L cell line was observed by using MTT assay and flow cytometry, respectively. The inhibition of metastasis and invasion in hepatocellular carcinoma cell line MHCC97L by Huanglian and Yunlian were compared as well. Results: Results of phytochemical analysis showed there were no significant differences between the two herbs&apos; ingredients and ratios. Also, there were no significant differences between Huanglian and Yunlian on cytotoxicity, apoptosis and metastasis in MHCC97L. Conclusion: Yunlian and Huanglian share great similarities in both chemical compostion and bioactivity in vitro. &#169; 2012 To C, et al.</description.abstract>
<language>eng</language>
<language>United States</language>
<publisher>Omics Publishing Group. The Journal&apos;s web site is located at http://www.omicsonline.org/jbbhome.php</publisher>
<relation.ispartof>Journal of Bioequivalence and Bioavailability</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<title>Comparison of components and anti-liver cancer activity in vitro between Huanglian and Yunlian</title>
<type>Article</type>
<description.nature>published_or_final_version</description.nature>
<identifier.doi>10.4172/jbb.1000118</identifier.doi>
<identifier.scopus>eid_2-s2.0-84866333908</identifier.scopus>
<identifier.hkuros>208630</identifier.hkuros>
<identifier.hkuros>217176</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-84866333908&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>4</identifier.volume>
<identifier.issue>6</identifier.issue>
<identifier.spage>86</identifier.spage>
<identifier.epage>90</identifier.epage>
<bitstream.url>http://hub.hku.hk/bitstream/10722/166083/1/Content.pdf</bitstream.url>
</item>
Author Affiliations
  1. The University of Hong Kong
  2. New York University
  3. Hubei University